HOW TO READ DATA
This interactive data visualization tool has been designed as a panoramic snapshot of the landscape of Phase II clinical studies. Recognized as the most critical and uncertain stage in drug development, Phase II trials serve as a gateway between early stage exploration and the final push towards regulatory approval. Compounds that demonstrate promise during this stage have a higher likelihood of ultimately reaching the market. This tool is envisioned to be a convenient resource for larger pharmaceutical companies interested in identifying potential acquisition targets among these promising Phase II trials.
Vanguard Companies, as referred to within this application, encompass all companies, research organizations, and institutions that are conducting Phase II clinical studies. These entities are distinct in that they are not affiliated with or owned by the 100 largest pharmaceutical companies, and they are reported in the clinicaltrials.gov database. Aside from the fact that these smaller, independent entities tend to be more likely acquisition targets due to their size, we chose to focus our investigation on these because such companies often exhibit greater flexibility and agility in their operations, characteristics that lend an additional layer of intrigue to our exploration.
"Active" clinical trial status, as classified by clinicaltrials.gov, incorporates several categories: "Recruiting", where the study is currently enrolling participants; "Enrolling by invitation", where participant recruitment is limited to a pre-specified population; "Active, not recruiting", where the study is ongoing but no longer enrolling new participants; and "Not yet recruiting", where the study is approved but not yet enrolling participants. We chose to focus only on "Recruiting" and "Active, not recruiting" because these two status categories indicate that study is ongoing and is not experiencing any issues in continuing to do so.
"Primary Diseases" refer to the main medical condition or disease being studied or the focus of the investigation during a clinical trial.
The term "Investigational New Drugs" within this application refers to the newly researched bioactive compounds or investigational agents. These are new drugs that have not been approved by the regulatory authorities and are under investigation in clinical trials.
Lastly, the scope of our data covers the time period from 2021 to 2023. Our choice of this timeframe stems from our interest in examining ongoing studies and trends. The studies that have been completed prior to this period, while valuable for historical context, do not align with our current focus on the present and future trajectory of Phase II clinical trials.
Vanguard Companies, as referred to within this application, encompass all companies, research organizations, and institutions that are conducting Phase II clinical studies. These entities are distinct in that they are not affiliated with or owned by the 100 largest pharmaceutical companies, and they are reported in the clinicaltrials.gov database. Aside from the fact that these smaller, independent entities tend to be more likely acquisition targets due to their size, we chose to focus our investigation on these because such companies often exhibit greater flexibility and agility in their operations, characteristics that lend an additional layer of intrigue to our exploration.
"Active" clinical trial status, as classified by clinicaltrials.gov, incorporates several categories: "Recruiting", where the study is currently enrolling participants; "Enrolling by invitation", where participant recruitment is limited to a pre-specified population; "Active, not recruiting", where the study is ongoing but no longer enrolling new participants; and "Not yet recruiting", where the study is approved but not yet enrolling participants. We chose to focus only on "Recruiting" and "Active, not recruiting" because these two status categories indicate that study is ongoing and is not experiencing any issues in continuing to do so.
"Primary Diseases" refer to the main medical condition or disease being studied or the focus of the investigation during a clinical trial.
The term "Investigational New Drugs" within this application refers to the newly researched bioactive compounds or investigational agents. These are new drugs that have not been approved by the regulatory authorities and are under investigation in clinical trials.
Lastly, the scope of our data covers the time period from 2021 to 2023. Our choice of this timeframe stems from our interest in examining ongoing studies and trends. The studies that have been completed prior to this period, while valuable for historical context, do not align with our current focus on the present and future trajectory of Phase II clinical trials.
